Charles P. Theuer M.D., Ph.D.
Net Worth

Last updated:

What is Charles P. Theuer M.D., Ph.D. net worth?

The estimated net worth of Dr. Charles P. Theuer M.D., Ph.D. is at least $9,066,661 as of 27 Apr 2023. He owns shares worth $12,861 as insider and has received compensation worth at least $9,053,800 in TRACON Pharmaceuticals, Inc..

What is the salary of Charles P. Theuer M.D., Ph.D.?

Dr. Charles P. Theuer M.D., Ph.D. salary is $905,380 per year as Chief Executive Officer, Pres & Director in TRACON Pharmaceuticals, Inc..

How old is Charles P. Theuer M.D., Ph.D.?

Dr. Charles P. Theuer M.D., Ph.D. is 61 years old, born in 1964.

What stocks does Charles P. Theuer M.D., Ph.D. currently own?

As insider, Dr. Charles P. Theuer M.D., Ph.D. owns shares in one company:

Company Title Shares Price per share Total value
TRACON Pharmaceuticals, Inc. (TCON) Chief Executive Officer, Pres & Director 399,417 $0.03 $12,861

What does TRACON Pharmaceuticals, Inc. do?

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of soft tissue sarcoma; and YH001, an investigational humanized CTLA-4 IgG1 monoclonal antibody for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors and lymphomas, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309; Case Western Reserve University for the development of TRC102; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.

TCON logo
TCON
TRACON Pharmaceuticals, Inc.
$0.03

Charles P. Theuer M.D., Ph.D. insider trading

TRACON Pharmaceuticals, Inc.

Dr. Charles P. Theuer M.D., Ph.D. has made 3 insider trades between 2015-2023, according to the Form 4 filled with the SEC. Most recently he purchased 47,000 units of TCON stock worth $35,250 on 27 Apr 2023.

The largest trade he's ever made was exercising 50,000 units of TCON stock on 9 Aug 2019. As of 27 Apr 2023 he still owns at least 399,417 units of TCON stock.

Transaction Date Security Shares Price per share Total value Source
Purchase
Common Stock 47,000 $0.75 $35,250
Purchase
Common Stock 3,999 $0.66 $2,639
Purchase
Common Stock 4,800 $1.52 $7,296
Purchase
Common Stock 200 $1.52 $304
Purchase
Common Stock 6,800 $1.62 $11,016
Purchase
Common Stock 23,000 $1.29 $29,762
Purchase
Common Stock 13,900 $1.41 $19,599
Purchase
Common Stock 9,200 $1.52 $13,984
Purchase
Common Stock 6,000 $1.59 $9,540
Purchase
Common Stock 5,000 $1.77 $8,850
Purchase
Common Stock 5,000 $1.67 $8,350
Purchase
Common Stock 5,000 $1.76 $8,800
Purchase
Common Stock 4,500 $1.85 $8,325
Purchase
Common Stock 3,000 $1.84 $5,520
Purchase
Common Stock 3,000 $1.87 $5,610
Purchase
Common Stock 2,500 $1.97 $4,925
Purchase
Common Stock 5,000 $1.97 $9,855
Purchase
Common Stock 4,500 $2.3 $10,350
Purchase
Common Stock 2,000 $2.5 $5,000
Purchase
Common Stock 4,000 $2.7 $10,800
Purchase
Common Stock 1,200 $2.45 $2,940
Purchase
Common Stock 3,500 $2.82 $9,870
Purchase
Common Stock 681 $2.88 $1,961
Purchase
Common Stock 4,000 $3.41 $13,652
Purchase
Common Stock 3,000 $3.56 $10,680
Purchase
Common Stock 11,000 N/A N/A
Purchase
Common Stock 1,000 N/A N/A
Purchase
Common Stock 2,000 N/A N/A
Purchase
Common Stock 5,000 N/A N/A
Purchase
Common Stock 5,000 N/A N/A
Purchase
Common Stock 10,000 N/A N/A
Purchase
Common Stock 10,000 $2.55 $25,500
Purchase
Common Stock 5,325 N/A N/A
Purchase
Common Stock 30,000 N/A N/A
Purchase
Common Stock 44,743 N/A N/A
Purchase
Common Stock 100 N/A N/A
Purchase
Common Stock 5,000 N/A N/A
Purchase
Common Stock 15,000 N/A N/A
Purchase
Common Stock 15,000 N/A N/A
Purchase
Common Stock 9,895 N/A N/A
Purchase
Common Stock 10,592 $1.9 $20,072
Purchase
Common Stock 10,592 N/A N/A
Purchase
Common Stock 4,100 N/A N/A
Purchase
Common Stock 10,000 N/A N/A
Purchase
Common Stock 10,000 $1.17 $11,720
Purchase
Common Stock 10,000 $1.17 $11,720
Purchase
Common Stock 10,000 N/A N/A
Purchase
Common Stock 10,000 N/A N/A
Purchase
Common Stock 50,000 N/A N/A
Purchase
Common Stock 49,000 N/A N/A
Option
Common Stock 10,000 N/A N/A
Option
Employee Stock Option (Right to Buy) 10,000 N/A N/A
Sale
Common Stock 10,000 N/A N/A
Sale
Common Stock 3,516 N/A N/A
Sale
Common Stock 100 N/A N/A

TRACON Pharmaceuticals key executives

TRACON Pharmaceuticals, Inc. executives and other stock owners filed with the SEC:

  • Dr. Charles P. Theuer M.D., Ph.D. (61) Chief Executive Officer, Pres & Director
  • Mr. Mark C. Wiggins M.B.A. (69) Chief Bus. Officer
  • Mr. Scott B. Brown CPA, M.S. (44) Chief Financial Officer